AYTU

Company Overview — What Does AYTU BIOPHARMA, INC Do?

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. AYTU BIOPHARMA, INC (AYTU) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joshua R. Disbrow and employs approximately 160 people. With a market capitalization of $28M, AYTU is one of the notable companies in the Healthcare sector.

AYTU BIOPHARMA, INC (AYTU) Stock Rating — Hold (April 2026)

As of April 2026, AYTU BIOPHARMA, INC receives a Hold rating with a composite score of 33.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AYTU ranks #1,937 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AYTU BIOPHARMA, INC ranks #206 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AYTU Stock Price and 52-Week Range

AYTU BIOPHARMA, INC (AYTU) currently trades at $2.55. The stock lost $0.01 (0.4%) in the most recent trading session. The 52-week high for AYTU is $3.06, which means the stock is currently trading -16.8% from its annual peak. The 52-week low is $0.95, putting the stock 168.4% above its annual trough. Recent trading volume was 29K shares, suggesting relatively thin trading activity.

Is AYTU Overvalued or Undervalued? — Valuation Analysis

AYTU BIOPHARMA, INC (AYTU) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.94x, versus the sector average of 2.75x. The price-to-sales ratio is 0.43x, compared to 1.66x for the average Healthcare stock.

At current multiples, AYTU BIOPHARMA, INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AYTU BIOPHARMA, INC Profitability — ROE, Margins, and Quality Score

AYTU BIOPHARMA, INC (AYTU) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -27.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.1% versus the sector average of -33.1%.

On a margin basis, AYTU BIOPHARMA, INC reports gross margins of 66.4%, compared to 71.5% for the sector. The operating margin is -5.3% (sector: -66.1%). Net profit margin stands at -7.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -8.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AYTU Debt, Balance Sheet, and Financial Health

AYTU BIOPHARMA, INC has a debt-to-equity ratio of 759.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.16x, suggesting adequate working capital coverage.

AYTU has a beta of 0.85, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for AYTU BIOPHARMA, INC is 40/100, reflecting average volatility within the normal range for its sector.

AYTU BIOPHARMA, INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, AYTU BIOPHARMA, INC reported revenue of $64M and earnings per share (EPS) of $-1.05. Net income for the quarter was $-4M. Gross margin was 66.4%. Operating income came in at $-3M.

In Q2 2026, AYTU BIOPHARMA, INC reported revenue of $15M and earnings per share (EPS) of $-1.05. Net income for the quarter was $-11M. Gross margin was 63.5%. Revenue grew -6.5% year-over-year compared to Q2 2025. Operating income came in at $-2M.

In Q1 2026, AYTU BIOPHARMA, INC reported revenue of $14M and earnings per share (EPS) of $0.21. Net income for the quarter was $2M. Gross margin was 66.1%. Revenue grew -16.2% year-over-year compared to Q1 2025. Operating income came in at $-2M.

In FY 2025, AYTU BIOPHARMA, INC reported revenue of $66M and earnings per share (EPS) of $-2.16. Net income for the quarter was $-14M. Gross margin was 69.0%. Revenue grew -18.0% year-over-year compared to FY 2024. Operating income came in at $-8M.

Over the past 8 quarters, AYTU BIOPHARMA, INC has experienced revenue contraction from $81M to $64M. Investors analyzing AYTU stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AYTU Dividend Yield and Income Analysis

AYTU BIOPHARMA, INC (AYTU) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AYTU Momentum and Technical Analysis Profile

AYTU BIOPHARMA, INC (AYTU) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AYTU vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AYTU BIOPHARMA, INC (AYTU) ranks #206 out of 838 stocks based on the Blank Capital composite score. This places AYTU in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AYTU against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AYTU vs S&P 500 (SPY) comparison to assess how AYTU BIOPHARMA, INC stacks up against the broader market across all factor dimensions.

AYTU Next Earnings Date

No upcoming earnings date has been announced for AYTU BIOPHARMA, INC (AYTU) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AYTU? — Investment Thesis Summary

AYTU BIOPHARMA, INC presents a balanced picture with arguments on both sides. The quality score of 22/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers.

In summary, AYTU BIOPHARMA, INC (AYTU) earns a Hold rating with a composite score of 33.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AYTU stock.

Related Resources for AYTU Investors

Explore more research and tools: AYTU vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AYTU head-to-head with peers: AYTU vs AZN, AYTU vs SLGL, AYTU vs VMD.